Health Topic

Cardiometabolic diseases

Optimizing cardiometabolic disease management together
Our commitment

We discover and develop novel, high-quality, accurate assays for innovative cardiometabolic biomarkers

As the leader in in vitro diagnostics, we discover and develop novel, high-quality, accurate assays for innovative biomarkers, through:

  • Continuous innovation: We aim to deliver on unmet medical needs to enable excellence in patient-centric decision-making.
  • Connecting solutions: We develop and offer innovative decision support and disease management solutions to optimize patient management across the continuum of care.
  • Creating evidence: We invest in evidence creation to gain new insights that will transform diagnostics and drive further development of CMD guidelines and policies, ultimately supporting improved outcomes for patients.
Disease burden

The impact of cardiometabolic diseases

Cardiometabolic diseases present a major healthcare burden1‑3 and cardiovascular diseases are a significant cause of premature death;1‑4 18.5 million deaths per year, one-third of all deaths globally.5

Cardiometabolic conditions form a continuum that starts from cardiovascular risk factors, and without intervention, can progress to myocardial infarction, stroke, heart failure, and death.21‑23 Due to this high interdependence, they can no longer be treated in isolation. Fragmented care can lead to redundant diagnostic testing and higher healthcare costs.22,29‑31

Diagnostic challenges and impact

The importance of diagnostics

Diagnostic tests play a crucial part in healthcare. They account for only a fraction of the total healthcare spending (<2%), while informing ~70% of clinical decisions.6

As the global market leader in in vitro diagnostics, Roche continuously invests in evidence generation on new uses of biomarkers to improve cardiometabolic care and outcomes for patients.10‑12 In 2023 alone, we invested CHF 13.2 million in research and development and delivered 6 new platforms, 21 diagnostic tests and 7 digital solutions,13 alongside CMD pipeline acceleration through partnerships and acquisitions.14

With biomarkers and digital solutions, Roche enables earlier diagnosis, reducing time to discharge, and providing information for personalized treatment plans.16,32

Benefits of Roche diagnostic and management solutions for cardiometabolic diseases


1. Timmis A, et al. Eur Heart J. 2020;41:12-85.

2. Savarese G, et al. Cardiovasc Res. 2022;118:3272-87.

3. Hasani WSR, et al. BMC Public Health. 2023;23:1561.

4. Roth GA, et al. Lancet. 2018;392:1736-88.

5. Our World in Data. Cardiovascular diseases. Available at: (Accessed March 2024).

6. Rohr, P., Binder, C., Dieterle, T., Giusti, F., Mario Messina, C. G., Toerien, E., Moch, H., & Schäfer, H. H. (2016). The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report. PLOS ONE, 11(3), e0149856.

7. Roche diagnostics. Cardiovascular disease and cardiac biomarkers. Available at: (Accessed March 2024).

8. Cobas. Elecsys ProBNP II. Available at: (Accessed March 2024).

9. Cobas. Elecsys Troponin T hs. Available at: (Accessed March 2024).

10. Mebazaa A, et al. Lancet. 2022;400:1938-52.

11. Huelsmann M, et al. J Am Coll Cardiol. 2013;62:1365-72.

12. Devereaux PJ, et al. JAMA. 2017;317:1642-51.

13. Roche. Annual Report 2023. Available at: (Accessed March 2024).

14. Roche. 2023 results. Available at: (Accessed March 2024).

15. Asian diabetes outcomes prevention trial (ADOPT) [NCT04286399]. Available at: (Accessed March 2024).

16. Twerenbold R, et al. Eur Heart J. 2016;37;3324-32.

17. Januzzi JL, et al. J Am Coll Cardiol. 2018;71:1191-200.

18. Badertscher P, et al. Clin Chem. 2018;64:515-25.

19. Stoyanov K, et al. Eur Heart J Acute Cardio Care. 2020;9:39-51.

20. Packer M, et al. Circulation. 2015;131:54-61.

21. Chrysant SG. Hippokratia. 2011;15:7-11.

22. Manla Y, Almahmeed W. Front Clin Diabetes Healthc. 2022;3:880468.

23. Vassiliadis E, et al. Biomark Insights. 2012;7;45-57.

24. Lin D, Akincigil A. Value in Health. 2019;22:S151.

25. Asheim A, et al. ESC Heart Fail. 2022;9:1884-90.

26. Robertson J, et al. BMC Health Serv Res. 2012;12:1-11.

27. Nair R, et al. Cureus. 2020;12:e7420.

28. Lesyuk W, et al. BMC Cardiovasc Disord. 2018;18:74.

29. Glynn LG. Lancet. 2009;374:1421-2.

30. Reiter-Brennan C, et al. Curr Cardiol Rep. 2021;23:22.

31. Bain S, et al. Br J Diabetes. 2021;21:89-95.

32. Pop-Busui R, et al. Diabetes Care. 2022;45:1670-90.

33. Cobas. CARDIAC POC ProBNP II metod sheet.

34. Schafer M, et al. Point of Care. 2010; 9:91-7.

35. Pelter MN, et al. Cardio Risk Reports. 2023;17:177-184.

36. Kim Y, et al. J Telemed Telecare. 2018;25(10).

37. Roche Healthcare Consulting. Available at (Accessed March 2024).

38. Medixine Press Release. Available at (Accessed March 2024).

39. Navify: Roche introduces Algo Suite. Available at (Accessed March 2024).

40. Halvorsen S, et al. Eur Heart J. 2022;43:3826-924.

41. Januzzi JL, et al. Eur Heart J. 2006;27:330-7.

42. Reichlin T, et al. Arch Intern Med. 2012;172:1211-8.

43. Mueller C, et al. Ann Emerg Med. 2016;68:76-87.

44. Zile MR, et al. J Am Coll Cardiol. 2016;68:2425-36.

45. Roffi M, et al. Eur Heart J. 2016;37:267-315.

46. Yancy CW, et al. Circ. 2017;136:e137-61.

47. Collet JP, et al. Eur Heart J. 2021;42:1289-367.

48. McDonagh TA, et al.. Eur Heart J. 2023;44:3627-39.

49. Maddox TM, et al. J Am Coll Cardiol. 2024;article in press.

50. ADA Standards of Care. Diabetes Care. 2024;47(Suppl. 1):S179–S218.

Found results in Articles